Granules India gets OAI classification from USFDA for Hyderabad facility

03 Dec 2024 Evaluate

Granules India’s Hyderabad facility inspection has been classified as ‘Official Action Indicated’ (OAI) by USFDA. The company has responded to all the observations issued by the US FDA. Additionally, the company has voluntarily undertaken a comprehensive evaluation of the facility for further enhancements that lead to improvement of the facility. This activity is undertaken in consultation with external subject matter experts.

The company will work with the US FDA on this activity and is confident that it will result in the US FDA approving the Company’s facility at Hyderabad in compliance with its expectations within a short time.

Earlier, the USFDA had issued Form 483 with 6 observations for said facility. 

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

534.65 0.20 (0.04%)
04-Dec-2024 13:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.00
Dr. Reddys Lab 1219.45
Cipla 1505.10
Lupin 2096.00
Zydus Lifesciences 969.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.